通过电技术生产的持续替代品的生物相容性和治疗性质的评估
Minjoo Cho1,2, Kyung Mi Shim1,2, Sang Soo Park3
1College of Veterinary Medicine and BK21 Four Program, Chonnam National University, Gwangju, Republic of Korea.
In vivo (Athens, Greece)
|April 30, 2024
概括
在动物研究中,Safe-Seal是一种新的合成耐久性替代品,证明了卓越的生物相容性,并促进了与现有产品相比的耐久性愈合.
科学领域:
- 生物材料科学 生物材料科学
- 神经外科 神经外科
- 组织工程是组织工程.
背景情况:
- 神经外科手术后持续重建是必不可少的,以防止脑脊髓液泄漏和感染等并发症.
- 开发理想的耐用替代品,无毒,生物相容,并提供长期的结构完整性,仍然是一个活跃的研究领域.
- 安全密封是一种使用电回旋技术开发的聚-L-乳酸合成可生物吸收的耐久替代品.
研究的目的:
- 评估Safe-Seal的生物相容性和治疗特性,这是一种新的电合成耐久替代品.
- 为了比较Safe-Seal的性能与负控制和商业上可用的持续替代品 (Redura®) 的性能.
主要方法:
- 使用电旋技术制造了Safe-Seal,并对其细胞毒性进行了评估.
- 一项体内研究涉及30只大鼠,分为三个组 (负控,安全密封,Redura®) 并在植入后4周和12周进行评估.
主要成果:
- 在动物模型中,Safe-Seal没有显示出细胞毒性或不良影响.
- 组织学分析显示,与负对照组相比,炎症细胞透率较低,对脑组织的粘附性降低.
- 安全密封证明了与商业产品Redura®相比的持续整合和愈合.
结论:
- 安全密封表现出足够的体内生物相容性,用于持久的修复.
- 这种合成可生物吸收的耐用替代品有效地支持硬质体的愈合,性能与市场领先的产品相似.
相关概念视频
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:17Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...